Skip to main content

Table 2 The QALE (quality-adjusted life expectancy), loss-of-QALE, healthcare expenditures (in US dollars) of lung cancer patients

From: Estimating the lifelong health impact and financial burdens of different types of lung cancer

  NSCLC (n = 59,787)
  SqCC (n = 16,796) Adenocarcinoma (n = 33,669) Other NSCLCs*(n = 9,322)
Age at diagnosis, mean (SD) years 69.35 (10.63) 65.60 (12.84) 68.12 (12.11)
Sex, no. of males (%) 14,423 (85.87) 18,075 (53.68) 6,625 (71.07)
Life expectancy, mean (SE) years 2.73 (0.02) 3.46 (0.02) 1.99 (0.02)
Expected years of life lost, mean (SE) years 11.84 (0.03) 14.61 (0.03) 13.91 (0.03)
QALE, mean (SE) QALY 2.37 (0.05) 3.03 (0.03) 1.74 (0.07)
Loss-of-QALE, mean (SE) QALY    
  Assumed mean utility of referents = 1 12.22 (0.05) 15.03 (0.04) 14.17 (0.08)
  Assumed mean utility of referents = 0.95 11.45 (0.05) 14.16 (0.03) 13.35 (0.08)
  Assumed mean utility of referents = 0.9 10.75 (0.05) 13.25 (0.04) 12.58 (0.08)
Lifetime healthcare expenditures per case,    
  NHI-reimbursed medical costs, mean (SE) $ 14,249 (1,435) 18,150 (1,469) 12,918 (1,156)
  Out-of-pocket medical costs, mean (SE) $ 6,350 (741) 18,620 (1,857) 7,439 (842)
Healthcare expenditures/life-year per case, mean (SE) $ 9,281 (803) 13,636 (754) 12,546 (1,050)
Healthcare expenditures/QALY per case, mean (SE) $ 10,841 (980) 15,642 (885) 14,475 (1,400)
  1. SD: standard deviation; SE: standard error; NSCLC: non-small cell lung cancer; QALY: quality-adjusted life year; SqCC: squamous cell carcinoma.
  2. *Large cell carcinoma, adenosquamous cell carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, carcinoid tumor and unspecified carcinoma.